NORGESTIMATE AND ETHINYL ESTRADIOL

Norgestimate And Ethinyl Estradiol Adverse Events Reported to the FDA Over Time

How are Norgestimate And Ethinyl Estradiol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Norgestimate And Ethinyl Estradiol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Norgestimate And Ethinyl Estradiol is flagged as the suspect drug causing the adverse event.

Most Common Norgestimate And Ethinyl Estradiol Adverse Events Reported to the FDA

What are the most common Norgestimate And Ethinyl Estradiol adverse events reported to the FDA?

Pregnancy On Oral Contraceptive	103 (11.84%)
Drug Ineffective	62 (7.13%)
Product Quality Issue	48 (5.52%)
Drug Interaction	28 (3.22%)
Off Label Use	22 (2.53%)
Drug Exposure During Pregnancy	18 (2.07%)
Metrorrhagia	18 (2.07%)
Cerebrovascular Accident	16 (1.84%)
Nausea	12 (1.38%)
Anxiety	11 (1.26%)
Headache	11 (1.26%)
	Show More
Blood Urine Present	10 (1.15%)
Coagulopathy	10 (1.15%)
Depression	10 (1.15%)
Thrombosis	10 (1.15%)
Vomiting	10 (1.15%)
Abortion Induced	9 (1.03%)
Mood Swings	9 (1.03%)
Abdominal Pain Upper	8 (.92%)
Abortion Spontaneous	8 (.92%)
Contraindication To Medical Treatme...	8 (.92%)
Deep Vein Thrombosis	8 (.92%)
Pain In Extremity	8 (.92%)
Pregnancy	8 (.92%)
Acne	7 (.8%)
Oedema Peripheral	7 (.8%)
Pulmonary Embolism	7 (.8%)
Fatigue	6 (.69%)
Injury	6 (.69%)
Muscle Spasms	6 (.69%)
Therapeutic Response Unexpected Wit...	6 (.69%)
Abdominal Pain	5 (.57%)
Convulsion	5 (.57%)
Dyspnoea	5 (.57%)
Eczema	5 (.57%)
Impaired Work Ability	5 (.57%)
Malaise	5 (.57%)
Migraine	5 (.57%)
Pain	5 (.57%)
Unintended Pregnancy	5 (.57%)
Vaginal Haemorrhage	5 (.57%)
Amenorrhoea	4 (.46%)
Bacterial Infection	4 (.46%)
Dysfunctional Uterine Bleeding	4 (.46%)
Hypoaesthesia	4 (.46%)
Intracranial Venous Sinus Thrombosi...	4 (.46%)
Swelling Face	4 (.46%)
Weight Increased	4 (.46%)
Abortion	3 (.34%)
Anaphylactoid Reaction	3 (.34%)
Anticonvulsant Drug Level Decreased	3 (.34%)
Chest Pain	3 (.34%)
Joint Swelling	3 (.34%)
Live Birth	3 (.34%)
Loss Of Consciousness	3 (.34%)
Menorrhagia	3 (.34%)
Menstruation Irregular	3 (.34%)
Ovarian Cyst	3 (.34%)
Pancreatitis	3 (.34%)
Paraesthesia	3 (.34%)
Polymenorrhoea	3 (.34%)
Pregnancy On Contraceptive	3 (.34%)
Proctocolectomy	3 (.34%)
Swelling	3 (.34%)
Syncope	3 (.34%)
Withdrawal Bleed	3 (.34%)
Abdominal Pain Lower	2 (.23%)
Alcohol Poisoning	2 (.23%)
Arthralgia	2 (.23%)
Back Pain	2 (.23%)
Blindness Unilateral	2 (.23%)
Blood Follicle Stimulating Hormone ...	2 (.23%)
Blood Prolactin Increased	2 (.23%)
Cardiac Arrest	2 (.23%)
Chest Discomfort	2 (.23%)
Cholecystectomy	2 (.23%)
Colitis Ischaemic	2 (.23%)
Colitis Ulcerative	2 (.23%)
Constipation	2 (.23%)
Decreased Appetite	2 (.23%)
Diarrhoea	2 (.23%)
Dizziness	2 (.23%)
Drug Administration Error	2 (.23%)
Drug Dose Omission	2 (.23%)
Dysphagia	2 (.23%)
Economic Problem	2 (.23%)
Embolism	2 (.23%)
Epilepsy	2 (.23%)
Feeling Abnormal	2 (.23%)
Gallbladder Disorder	2 (.23%)
Groin Pain	2 (.23%)
Haematochezia	2 (.23%)
Haematocrit Decreased	2 (.23%)
Haemoglobin Decreased	2 (.23%)
Hormone Level Abnormal	2 (.23%)
Incontinence	2 (.23%)
Intra-uterine Death	2 (.23%)
Irritability	2 (.23%)
Maternal Drugs Affecting Foetus	2 (.23%)
Menstrual Disorder	2 (.23%)
Micturition Disorder	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Norgestimate And Ethinyl Estradiol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Norgestimate And Ethinyl Estradiol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Norgestimate And Ethinyl Estradiol

What are the most common Norgestimate And Ethinyl Estradiol adverse events reported to the FDA?

Pregnancy, Labour, Delivery And Pos...	123 (14.14%)
Therapeutic And Nontherapeutic Effe...	96 (11.03%)
Product Quality Issues	52 (5.98%)
Gastrointestinal Signs	43 (4.94%)
Menstrual Cycle And Uterine Bleedin...	43 (4.94%)
Central Nervous System Vascular	23 (2.64%)
Embolism And Thrombosis	23 (2.64%)
Therapeutic Procedures And Supporti...	23 (2.64%)
Chemical Injury And Poisoning	22 (2.53%)
Epidermal And Dermal Conditions	20 (2.3%)
Neurological	17 (1.95%)
	Show More
Headaches	16 (1.84%)
Musculoskeletal And Connective Tiss...	16 (1.84%)
Abortions And Stillbirth	15 (1.72%)
Anxiety Disorders	14 (1.61%)
Lifestyle Issues	14 (1.61%)
Mood Disorders	12 (1.38%)
Coagulopathies And Bleeding Diathes...	10 (1.15%)
Depressed Mood Disorders	10 (1.15%)
Renal And Urinary Tract Investigati...	10 (1.15%)
Endocrine Investigations	9 (1.03%)
Injuries	9 (1.03%)
Obstetric And Gynecological Therape...	9 (1.03%)
Skin Appendage Conditions	9 (1.03%)
Bacterial Infectious	8 (.92%)
Hematology Investigations	8 (.92%)
Muscle	8 (.92%)
Pulmonary Vascular	8 (.92%)
Respiratory	8 (.92%)
Seizures	8 (.92%)
Medication Errors	6 (.69%)
Vulvovaginal Disorders	6 (.69%)
Joint	5 (.57%)
Physical Examination Topics	5 (.57%)
Allergic Conditions	4 (.46%)
Exocrine Pancreas Conditions	4 (.46%)
Gastrointestinal Inflammatory Condi...	4 (.46%)
Gastrointestinal Motility And Defec...	4 (.46%)
Urinary Tract Signs	4 (.46%)
Vision	4 (.46%)
Angiedema And Urticaria	3 (.34%)
Appetite And General Nutritional	3 (.34%)
Cardiac Arrhythmias	3 (.34%)
Cardiac Disorder Signs	3 (.34%)
Coronary Artery	3 (.34%)
Gastrointestinal Therapeutic Proced...	3 (.34%)
Hepatobiliary	3 (.34%)
Ovarian And Fallopian Tube	3 (.34%)
Reproductive Tract	3 (.34%)
Toxicology And Therapeutic Drug Mon...	3 (.34%)
Arteriosclerosis, Stenosis, Vascula...	2 (.23%)
Cardiac And Vascular Disorders Cong...	2 (.23%)
Demyelinating	2 (.23%)
Economic And Housing Issues	2 (.23%)
Gallbladder	2 (.23%)
Gastrointestinal Hemorrhages	2 (.23%)
Hepatic And Biliary Neoplasms Benig...	2 (.23%)
Hepatic And Hepatobiliary	2 (.23%)
Hepatobiliary Therapeutic Procedure...	2 (.23%)
Infections - Pathogen Unspecified	2 (.23%)
Movement Disorders	2 (.23%)
Personality Disorders	2 (.23%)
Platelet	2 (.23%)
Red Blood Cell	2 (.23%)
Sleep Disorders	2 (.23%)
Suicidal And Self-injurious Behavio...	2 (.23%)
Upper Respiratory Tract Disorders	2 (.23%)
Adrenal Gland	1 (.11%)
Body Temperature Conditions	1 (.11%)
Bone And Joint Therapeutic Procedur...	1 (.11%)
Breast	1 (.11%)
Breast Neoplasms Malignant And Unsp...	1 (.11%)
Cardiac And Vascular Investigations	1 (.11%)
Deliria	1 (.11%)
Endocrine Disorders Of Gonadal Func...	1 (.11%)
Enzyme	1 (.11%)
Family Issues	1 (.11%)
Fungal Infectious	1 (.11%)
Gastrointestinal Conditions	1 (.11%)
Hemolyses And Related Conditions	1 (.11%)
Malabsorption Conditions	1 (.11%)
Maternal Complications Of Pregnancy	1 (.11%)
Neonatal And Perinatal Conditions	1 (.11%)
Nephropathies	1 (.11%)
Nervous System Neoplasms Benign	1 (.11%)
Neurological Disorders Of The Eye	1 (.11%)
Parathyroid Gland	1 (.11%)
Peripheral Neuropathies	1 (.11%)
Psychiatric	1 (.11%)
Sexual Dysfunctions, Disturbances A...	1 (.11%)
Skin And Subcutaneous Tissue	1 (.11%)
Skin Vascular Abnormalities	1 (.11%)
Thyroid Gland	1 (.11%)
Tissue	1 (.11%)
Vascular Hemorrhagic	1 (.11%)
Vascular Hypertensive	1 (.11%)
Vascular Inflammations	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Norgestimate And Ethinyl Estradiol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Norgestimate And Ethinyl Estradiol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.